Intravenous prostacyclin mitigates inhaled nitric oxide rebound effect: A case control study

Artificial Organs

Volumn 23, Issue 11, 1999, Pages 975-978

  Hermon, Michael ^a   Golej, Johann ^a   Burda, Gudrun ^a   Marx, Manfred ^a   Trittenwein, Gerhard ^a   Pollak, Arnold ^a  

^a ST ANNA CHILDREN S HOSPITAL   (Austria)

Author keywords

Extracorporeal membrane oxygenation; Inhaled nitric oxide; Prostacyclin; Pulmonary hypertension; Rebound effect

Indexed keywords

NITRIC OXIDE; OXYGENATION;

CASE-CONTROL STUDY; CONGENITAL HEART DEFECTS; ENDOTHELIAL FUNCTION; EXTRACORPOREAL MEMBRANE OXYGENATION; INHALED NITRIC OXIDE; ITS APPLICATIONS; PROSTACYCLIN; PULMONARY HYPERTENSION; REBOUND-EFFECT; SURGICAL REPAIR;

RESPIRATORY THERAPY;

NITRIC OXIDE; PROSTACYCLIN;

CASE CONTROL STUDY; CHILD; CLINICAL ARTICLE; CONFERENCE PAPER; DRUG EFFECT; EXTRACORPOREAL OXYGENATION; FEMALE; HUMAN; INFANT; INHALATIONAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LUNG BLOOD FLOW; LUNG ENDOTHELIUM; LUNG VASCULAR RESISTANCE; MALE; NEWBORN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REBOUND; RETROSPECTIVE STUDY; TACHYPHYLAXIS;

EID: 0032752161     PISSN: 0160564X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1594.1999.06448.x     Document Type: Conference Paper

References (27)

1. Goldman AP, Delius RE, Deanfield JE, Macrae DJ. Nitric oxide is superior to prostacyclin for pulmonary hypertension after cardiac operation. Ann Thorac Surg 1995;60:300-6.
2. Dhillon R, Pearson GA, Firmin RK, Chan KC, Leanage R. Extracorporeal membrane oxygenation and the treatment of critical pulmonary hypertension in congenital heart disease. Eur J Cardiothorac Surg 1995;9:553-6.
3. Dalton HJ, Siewers RD, Fuhrman BP, Del-Nido P, Thompson AE, Shaver MG, Downy M. Extracorporeal membrane oxygenation for cardiac rescue in children with severe myocardial dysfunction. Crit Care Med 1993;21:1020-8.
4. Delius RE, Bove EL, Meliones JN, Custer JR, Moler FW, Crowley D, Amirikia A, Behrendt DM, Bartlett RH. Use of extracorporeal support in patients with congenital heart disease. Crit Care Med 1992;20:1216-22.
5. Wessel DL, Adatia I, Giglia TM, Thompson JE, Kulik TJ. Use of inhaled nitric oxide and acetylcholine in the evaluation of pulmonary hypertension and endothelial function after cardiopulmonary bypass. Circulation 1993;88(Part 1):2128-38.
6. Turner-Gomes SO, Andrew M, Coles J, Truster GA, Williams WG, Rabinovitch M. Abnormalities in von Willebrand factor and antithrombin III after cardiopulmonary bypass operations for congenital heart disease. J Thorac Cardiovasc Surg 1992;103:87-97.
7. Koul B, Willen H, Sjoberg T, Wetterberg T, Kugelberg J, Steen S. Pulmonary sequelae of prolonged total venoarterial bypass: Evaluation with a new expiremental model. Ann Thorac Surg 1991;51:794-9.
8. Roberts JD, Polaner DM, Lang P, Zapol WM. Inhaled nitric oxide in persistent pulmonary hypertension of the newborn. Lancet 1992;340:818-9.
9. Kinsella JP, Neish SR, Shaffer E, Abman SH. Low dose inhalational nitric oxide in persistent pulmonary hypertension of newborn. Lancet 1992;340:819-20.
10. Abman SH, Griebel JL, Packer DK, Schmidt JM, Swanton D, Kinsella JP. Acute effects of inhaled nitric oxide in children with severe hypoxemic respiratory failure. J Pediatr 1994;124: 881-4.
11. Roberts JD, Lang P, Bigatello LM, Vlahakes GJ, Zapol WM. Inhaled nitric oxide in congenital heart disease. Circulation 1993;87:447-53.
12. Adatia I, Lillehei C, Arnold JH, Thompson JE, Palazzo R, Fackler JC, Wessel DL. Inhaled nitric oxide in the treatment of postoperative graft dysfunction after lung transplantation. Ann Thorac Surg 1994;57:1311-8.
13. Packer M, Meller J, Medina W, Gorlin R, Herman MV. Rebound hemodynamic events after abrupt withdrawal of nitroprusside in patients with severe chronic heart failure. N Engl J Med 1979;301:1193-7.
14. Schranz D, Huth R, Wippermann CF, Ritzerfeld S, Schmitt FX, Oelert H. Nitric oxide and prostacyclin lower suprasystemic pulmonary hypertension after cardiopulmonary bypass. Eur J Pediair 1993;152:793-6
15. Kinsella JP, McCurnin DC, Clark RH. Cardiac performance in ECMO candidates: Echocardiographic predictors for ECMO. J Pediatr Surg 1992;27:44-7.
16. Assreuy J, Cunha FQ, Liew FW, Moncada S. Feedback inhibition of nitric oxide sythase activity by nitric oxide. Eur J Pharmacol 1993;108:833-7.
17. Ravichandran LV, Johns RA, Renqasamy A. Direct and reversible inhibition of endothelial nitric oxide synthase by nitric oxide. Am J Physiol 1995;268:H2216-23.
18. Atz AM, Adatia I, Wessel DL. Rebound pulmonary hypertension after inhalation of nitric oxide. Ann Thorac Surg 1996; 62:1759-64.
19. Hopkins RA, Bull C, Haworth SG, de Levai MR, Stark J. Pulmonary hypertensive crises following surgery for congenital heart defects in young children. Eur J Cardiothorac Surg 1991;5:625-34.
20. Bush A, Busst CM, Knight WB, Shinebourne EA. Comparison of the hemodynamic effects of epoprostenol (prostacyclin) and tolazoline. Br Heart J 1988;60:141-8.
21. Hall SM, Haworth SG. Onset and evolution of pulmonary vascular disease in young children: abnormal postnatal remodeling studied in lung biopsies. J Pathol 1992;166:183-93.
22. Celermajer DS, Cullen S, Deanfield JE. Impairment of endothelium-dependent pulmonary artery relaxation in children with congenital heart disease and abnormal pulmonary hemodynamics. Circulation 1993;87:440-6.
23. Smith EEJ, Naftel DC, Blackstone EH, Kirklin JW. Microvascular permeability after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1987;94:225-33.
24. Hickey PR, Hansen DD. Pulmonary hypertension in infants: Postoperative management. In: Yacoub M, ed. Annual of Cardiac Surgery. London: Current Science, 1989:16-22.
25. Vane JR. Nobel lecture. Adventures and excursions in bioassay the stepping stones to prostacyciin. Postgrad Med J 1983; 59:743-58.
26. Palmer RMJ, Ferrige AG, Moncada S. Nitric oxide release accounts for biological activity of endothelium-derived relaxing factor. Nature 1987;327:524-6.
27. Rossaint R, Falke KJ, Lopez F. Inhaled nitric oxide for the adult respiratory distress syndrome. N Engl J Med 1993;328: 399-405.